ASBP (Aspire-Lakewood Holdings) Altman Z-Score: 1.71 (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASBP Aspire-Lakewood Holdings Inc ASBP
11 GF Score
Price $9.25
! 2 Warning Signs
View Full Analysis

What is Aspire-Lakewood Holdings Altman Z-Score?

Aspire-Lakewood Holdings ASBP +2.42% 11 Altman Z-Score is 1.71 as of Sep. 11, 2026. GuruFocus rates ASBP with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 931 Biotechnology companies, Aspire-Lakewood Holdings ranks worse than 57.79% on this metric.

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 1.55 is in distress zone. This implies bankruptcy possibility in the next two years.

Aspire-Lakewood Holdings has a Altman Z-Score of 1.71, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Aspire-Lakewood Holdings's Altman Z-Score or its related term are showing as below:

ASBP' s Altman Z-Score Range Over the Past 10 Years
Min: -73.48   Med: -24.3   Max: 1.55
Current: 1.55

During the past 4 years, Aspire-Lakewood Holdings's highest Altman Z-Score was 1.55. The lowest was -73.48. And the median was -24.30.


Aspire-Lakewood Holdings  (NAS:ASBP) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Aspire-Lakewood Holdings Altman Z-Score Related Terms


Aspire-Lakewood Holdings Altman Z-Score Historical Data

* Premium members only.

The historical data trend for Aspire-Lakewood Holdings's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aspire-Lakewood Holdings Altman Z-Score Chart

Aspire-Lakewood Holdings Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Altman Z-Score
0.00 0.00 0.00 -73.48

Aspire-Lakewood Holdings Quarterly Data
Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -43.33 -73.48 -5.26 -0.33

ASBP vs PDSB, KPRX, SNTI: Altman Z-Score Comparison

For the Biotechnology subindustry, Aspire-Lakewood Holdings's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspire-Lakewood Holdings Altman Z-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aspire-Lakewood Holdings's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Aspire-Lakewood Holdings's Altman Z-Score falls into.


ASBP
11GF Score
Aspire-Lakewood Holdings Inc ASBP
Altman Z-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aspire-Lakewood Holdings Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Aspire-Lakewood Holdings's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.87+1.4*-2.3447+3.3*-0.1286+0.6*7.2765+1.0*0.0072
=1.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Jun. 2026:
Total Assets was $13.54 Mil.
Total Current Assets was $13.47 Mil.
Total Current Liabilities was $1.69 Mil.
Retained Earnings was $-31.75 Mil.
Pre-Tax Income was -1.268 + -3.223 + -4.708 + -1.85 = $-11.05 Mil.
Interest Expense was 0 + -1.595 + -6.233 + -1.48 = $-9.31 Mil.
Revenue was 0.063 + 0.028 + 0.004 + 0.002 = $0.10 Mil.
Market Cap (Today) was $12.97 Mil.
Total Liabilities was $1.78 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(13.466 - 1.686)/13.541
=0.87

X2=Retained Earnings/Total Assets
=-31.749/13.541
=-2.3447

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-11.049 - -9.308)/13.541
=-0.1286

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=12.974/1.783
=7.2765

X5=Revenue/Total Assets
=0.097/13.541
=0.0072

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Aspire-Lakewood Holdings has a Altman Z-Score of 1.71 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.

Frequently Asked Questions Learn more about Altman Z-Score →
What does a Altman Z-Score of 1.71 mean?
Aspire-Lakewood Holdings (ASBP) has a Altman Z-Score of 1.71 as of Sep. 11, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Aspire-Lakewood Holdings and its competitors. According to the industry distribution chart, Aspire-Lakewood Holdings ranks #538 out of 931 companies in the Biotechnology industry, placing it in the top 57.8%.
Is Aspire-Lakewood Holdings' Altman Z-Score too high?
Aspire-Lakewood Holdings' current Altman Z-Score is 1.71. The Biotechnology industry median Altman Z-Score is 2.62. Aspire-Lakewood Holdings' value of 1.71 is 34.7% below this industry median. Based on the distribution chart, Aspire-Lakewood Holdings ranks #538 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aspire-Lakewood Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Aspire-Lakewood Holdings' Altman Z-Score compare to PDSB and KPRX?
According to the Biotechnology industry distribution chart, Aspire-Lakewood Holdings ranks #538 out of 931 companies for Altman Z-Score. This places Aspire-Lakewood Holdings in the lower half of its industry. The industry median Altman Z-Score is 2.62. Aspire-Lakewood Holdings' value of 1.71 is 34.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.62, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspire-Lakewood Holdings's current Altman Z-Score of 1.71 is 34.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Aspire-Lakewood Holdings and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspire-Lakewood Holdings's current Altman Z-Score is 1.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspire-Lakewood Holdings stock overvalued right now?
Aspire-Lakewood Holdings (ASBP) has a current Altman Z-Score of 1.71. The current Altman Z-Score is 1.71 and 34.7% below the Biotechnology industry median of 2.62. Aspire-Lakewood Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Aspire-Lakewood Holdings (ASBP), the current Altman Z-Score is 1.71 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aspire-Lakewood Holdings Business Description

Address 23150 Fashion Drive, Suite 232, Estero, FL, USA, 33928
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
11GF Score

Get the complete analysis for ASBP

Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.25
Price